FC
ACAD icon

Finepoint Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Finepoint Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-905,384
Closed -$13.9M – 27
2024
Q3 		$13.9M Hold
905,384
– – 1.01% 14
2024
Q2 		$14.7M Buy
905,384
+64,931
+8% +$1.05M 4.18% 9
2024
Q1 		$15.5M Buy
840,453
+70,800
+9% +$1.75M 3.99% 11
2023
Q4 		$24.1M Buy
769,653
+213,100
+38% +$5.09M 7.6% 3
2023
Q3 		$11.6M Sell
556,553
-290,400
-34% -$7.89M 5.78% 11
2023
Q2 		$20.3M Sell
846,953
-69,400
-8% -$1.54M 7.02% 3
2023
Q1 		$17.2M Sell
916,353
-260,477
-22% -$4.96M 6.59% 4
2022
Q4 		$18.7M Buy
1,176,830
+65,800
+6% +$1.03M 6.06% 4
2022
Q3 		$18.2M Buy
1,111,030
+403,830
+57% +$6.54M 5.98% 5
2022
Q2 		$9.96M Buy
+707,200
New +$13.2M 3.45% 17

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Finepoint Capital's ACAD Position: Q4 2024 in Review

Finepoint Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 905,384 shares — an estimated $13.9M sold.

Finepoint Capital first reported a position in ACAD in Q2 2022 and held it in 10 quarters. The position peaked at $24.1M in Q4 2023. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • Finepoint Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Finepoint Capital sold 905,384 Acadia Pharmaceuticals shares in Q4 2024, an estimated $13.9M.
  • Finepoint Capital first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Finepoint Capital's Acadia Pharmaceuticals position peaked at $24.1M in Q4 2023.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Finepoint Capital's 13F filing for Q4 2024, filed 13 Feb 2025.